RCM
RGLS

RA Capital Management’s Regulus Therapeutics RGLS Stock Holding History

RA Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-336,843
Closed -$532K – 95
2024
Q4 		$532K Sell
336,843
-429,991
-56% -$661K 0.01% 88
2024
Q3 		$1.2M Sell
766,834
-5,483,166
-88% -$9.07M 0.01% 80
2024
Q2 		$11.2M Hold
6,250,000
– – 0.15% 65
2024
Q1 		$18M Buy
+6,250,000
New +$10.2M 0.23% 66
2016
Q2 		– Sell
-8,709
Closed -$7.24M – 37
2016
Q1 		$7.24M Sell
8,709
-20,315
-70% -$16.2M 0.93% 28
2015
Q4 		$30.4M Sell
29,024
-4,641
-14% -$4.65M 3.01% 10
2015
Q3 		$26.4M Buy
33,665
+2,078
+7% +$2.13M 3.79% 6
2015
Q2 		$41.5M Buy
31,587
+1,665
+6% +$2.69M 4.18% 6
2015
Q1 		$60.8M Sell
29,922
-9,602
-24% -$20.9M 6.04% 5
2014
Q4 		$76.1M Buy
+39,524
New +$70.3M 8.18% 4

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RA Capital Management's RGLS Position: Q1 2025 in Review

RA Capital Management sold out of Regulus Therapeutics (RGLS) in Q1 2025, closing a stake of 336,843 shares — an estimated $532K sold.

RA Capital Management first reported a position in RGLS in Q4 2014 and held it in 10 quarters. The position peaked at $76.1M in Q4 2014. 75 funds tracked by Wall St. Rank hold RGLS as of Q1 2025.

  • RA Capital Management reported no remaining Regulus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • RA Capital Management sold 336,843 Regulus Therapeutics shares in Q1 2025, an estimated $532K.
  • RA Capital Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 10 quarters.
  • RA Capital Management's Regulus Therapeutics position peaked at $76.1M in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2025.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.